Highlight
This comprehensive registry analysis involving 343 heavily pretreated multiple myeloma patients demonstrates a superior overall response rate, progression-free survival, and complete remission attainment with ciltacabtagene autoleucel (cilta-cel) compared to idecabtagene vicleucel (ide-cel). Notably, cilta-cel shows a greater capacity for remission conversion and durable outcomes. Safety profiles were comparable with manageable toxicities. These findings emphasize the importance of individualized CAR T-cell therapy selection in real-world clinical practice.
